Aspreva Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
Posted on: Monday, 18 September 2006, 15:01 CDT
VICTORIA, BC, Sept. 18 /PRNewswire-FirstCall/ -- Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today announced that Noel Hall, President and Co-Founder, will be presenting at the UBS Global Life Sciences Conference in New York.
The 30 minute presentation will be followed by a 30 minute break out session and will take place on Tuesday, September 26th at 10:30 am ET at the Grand Hyatt.
A live audio web cast of the presentation will be available to all interested parties through a link posted on Aspreva's website at http://www.aspreva.com/ in the Investors section.
About Aspreva Pharmaceuticals
Aspreva is an emerging pharmaceutical company focused on identifying, developing and, upon regulatory approval, commercializing new indications for approved drugs and late stage drug candidates for patients living with less common diseases. Aspreva's strategy allows its partners to maintain core brand focus while extending the benefits of their medicines to a broader patient population. Aspreva is listed on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV".
CONTACT: Sage Baker, VP, Investor Relations & Corporate Communications, Aspreva Pharmaceuticals, (250) 744-2488 ext. 84270, sbaker@aspreva.com
Aspreva Pharmaceuticals
CONTACT: Sage Baker, VP, Investor Relations & Corporate Communications,Aspreva Pharmaceuticals, (250) 744-2488 ext. 84270, sbaker@aspreva.com
Source: PRNewswire-FirstCall
Related Articles
- Upstream Biosciences Appoints Dr. Michael Hayden Killam Professor of Medical Genetics and the Canada Research Chair in Human Genetics to Its Scientific Advisory Board
- Aspreva Provides Update On Lupus Nephritis Development Program
- Lupus Foundation of America Statement on Results for Clinical Study of CellCept(R) Released By Aspreva Pharmaceutical Company
- CellCept Gets Orphan Status in Rare Immune Disorder
- Aspreva Pharmaceuticals to Present at the Windhover Pharmaceutical Strategic Outlook Conference
- Aspreva and Roche Drug Receives FDA Orphan Designation
- Aspreva Pharmaceuticals Increases Revenue Guidance for Fiscal 2005
- Aspreva Pharmaceuticals to Present at the CIBC World Markets Healthcare Conference in New York
- Pacific Exchange to Trade Five New Options
 |
 |
User Comments (0)
RSS Feeds